Abstract：
UNASSIGNED: This study aims to provide a comprehensive assessment of economic and health-related quality of life (HRQoL) outcomes for human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer patients treated with trastuzumab-containing regimens, by focusing on both Incremental Cost-Effectiveness Ratios (ICERs) and quality-adjusted life years (QALYs).
UNASSIGNED: A systematic search was conducted across PubMed, Embase, and Scopus databases without language or publication year restrictions. Two independent reviewers screened eligible studies, extracted data, and assessed methodology and reporting quality using the Drummond checklist and Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022), respectively. Costs were converted to US dollars (US$) for 2023 for cross-study comparison.
UNASSIGNED: Twenty-two articles, primarily from high-income countries (HICs), were included, with ICERs ranging from US$13,176/QALY to US$254,510/QALY, falling within country-specific cost-effectiveness thresholds. A notable association was observed between higher QALYs and lower ICERs, indicating a favorable cost-effectiveness and health outcome relationship. EQ-5D was the most utilized instrument for assessing health state utility values, with diverse targeted populations.
UNASSIGNED: Studies reporting higher QALYs tend to have lower ICERs, indicating a positive relationship between cost-effectiveness and health outcomes. However, challenges such as methodological heterogeneity and transparency in utility valuation persist, underscoring the need for standardized guidelines and collaborative efforts among stakeholders.
UNASSIGNED: PROSPERO ID: CRD42021259826.
UNASSIGNED: A systematic search was conducted across PubMed, Embase, and Scopus databases without language or publication year restrictions. Two independent reviewers screened eligible studies, extracted data, and assessed methodology and reporting quality using the Drummond checklist and Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022), respectively. Costs were converted to US dollars (US$) for 2023 for cross-study comparison.
UNASSIGNED: Twenty-two articles, primarily from high-income countries (HICs), were included, with ICERs ranging from US$13,176/QALY to US$254,510/QALY, falling within country-specific cost-effectiveness thresholds. A notable association was observed between higher QALYs and lower ICERs, indicating a favorable cost-effectiveness and health outcome relationship. EQ-5D was the most utilized instrument for assessing health state utility values, with diverse targeted populations.
UNASSIGNED: Studies reporting higher QALYs tend to have lower ICERs, indicating a positive relationship between cost-effectiveness and health outcomes. However, challenges such as methodological heterogeneity and transparency in utility valuation persist, underscoring the need for standardized guidelines and collaborative efforts among stakeholders.
UNASSIGNED: PROSPERO ID: CRD42021259826.
摘要：
■本研究旨在对人类表皮生长因子受体2（HER2）阳性的经济和健康相关生活质量（HRQoL）结果进行综合评估，早期乳腺癌患者接受含有曲妥珠单抗的方案治疗,通过关注增量成本效益比(ICER)和质量调整生命年(QALYs)。
■在PubMed进行了系统搜索，Embase,和Scopus数据库没有语言或出版年份限制。两名独立审核员筛选了符合条件的研究，提取的数据，并使用Drummond检查表和2022年综合卫生经济评估报告标准（CHEERS2022）评估方法和报告质量，分别。2023年的成本转换为美元（US$），用于跨研究比较。
■22篇文章，主要来自高收入国家(HIC)，包括在内，ICER从13,176美元/QALY到254,510美元/QALY，在特定国家的成本效益阈值内。在较高的QALYs和较低的ICER之间观察到显著的关联，表明有利的成本效益和健康结果关系。EQ-5D是评估健康状况效用值最常用的工具，不同的目标人群。
■报告较高QALYs的研究往往具有较低的ICER，表明成本效益与健康结果之间存在正相关关系。然而,公用事业估值的方法论异质性和透明度等挑战依然存在，强调需要制定标准化准则和利益攸关方之间的合作努力。
■PROSPEROID：CRD42021259826。
■在PubMed进行了系统搜索，Embase,和Scopus数据库没有语言或出版年份限制。两名独立审核员筛选了符合条件的研究，提取的数据，并使用Drummond检查表和2022年综合卫生经济评估报告标准（CHEERS2022）评估方法和报告质量，分别。2023年的成本转换为美元（US$），用于跨研究比较。
■22篇文章，主要来自高收入国家(HIC)，包括在内，ICER从13,176美元/QALY到254,510美元/QALY，在特定国家的成本效益阈值内。在较高的QALYs和较低的ICER之间观察到显著的关联，表明有利的成本效益和健康结果关系。EQ-5D是评估健康状况效用值最常用的工具，不同的目标人群。
■报告较高QALYs的研究往往具有较低的ICER，表明成本效益与健康结果之间存在正相关关系。然而,公用事业估值的方法论异质性和透明度等挑战依然存在，强调需要制定标准化准则和利益攸关方之间的合作努力。
■PROSPEROID：CRD42021259826。
